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Background
Iron overload is a predictable and life-threatening complication in patients dependent on 
the regular transfusion of RBCs. The aims of this study were to investigate the efficacy 
and safety of deferiprone in a variety of pediatric hematologic and/or oncologic patients 
with a high iron overload.
Methods
Seventeen patients (age: 1.1-20.4 years; median: 10.6 years) from 7 hospitals who were 
treated with deferiprone from 2006 to 2009 were enrolled in this study. Medical records 
of enrolled patients were reviewed retrospectively.
Results
Serum ferritin levels were 4,677.8±1,130.9 μg/L at baseline compared to 3,363.9±
1,149.7 μg/L at the end of deferiprone treatment (P=0.033). Only 1 patient developed 
neutropenia as a complication.
Conclusion
Deferiprone treatment is relatively safe for pediatric patients suffering from various hema-
tologic and oncologic diseases that require RBC transfusions as part of treatment. 
However, the potential development of critical complications such as agranulocytosis 
and/or neutropenia remains a concern.
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INTRODUCTION
  Iron overload is a predictable and life-threatening compli-
cation in patients dependent on the regular transfusion of 
RBCs. In the absence of effective iron chelation therapy, 
chronic transfusions lead to iron accumulation in the liver, 
various endocrine organs, and the heart [1]. Numerous studies 
have reported that cardiac events due to iron overload in 
the heart are the primary cause of death in these patients 
[2-4]. Therefore, effective iron chelation to promote the 
excretion of the excess iron from target organs is essential 
to prevent the morbidity and mortality observed in patients 
with transfusion-dependent hematologic and/or oncologic 
disorders [5, 6].
  Over the past decades, deferoxamine (Desferal) has been 
shown to prolong survival; improve growth and sexual matu-
ration; and reduce hepatic, cardiac, and endocrine dysfunc-
tion in iron-overloaded patients [7]. Although deferoxamine 
can effectively stabilize or reduce body iron load, compliance 
with the demanding dose regimen can be an issue. Subcuta-
neous administration of this drug is frequently associated 
with local irritation at the site of the deferoxamine infusion. 
Moreover, deferoxamine has been associated with a variety 
of dose-related toxicities such as visual and auditory neuro-
toxicity, growth retardation, and bone morbidities. Due to 
these complications and the route of administration, many 
patients are noncompliant with deferoxamine therapy and 
therefore fail to achieve adequate iron chelation [1, 8-11].
  Deferiprone (Ferriprox) is an iron-chelating agent in oral 
tablet form whose efficacy has been shown to be equivalent 
to that of deferoxamine [12-16]. In this study, we investigated 
the efficacy and safety of deferiprone in a variety of pediatric Korean J Hematol 2010;45:58-61.
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Fig. 1. Serum ferritin concentrations of all patients at baseline (    ) versus
end of study (    ). Compared to baseline, the decline in serum ferritin 
levels at the end of the study was statistically significant (P= 0.033).
Table 1. Patient characteristics.
Characteristics N
Age (yr) 1.1-20.4 
(median, 10.6)
Male：Female 6：11
RBC transfusion before study 3-330 units
(median, 48 units)
Period from diagnosis to treatment (yr) 0.7-20.3
(median, 3.5)
Treatment duration (mo) 1.4-39.6
(median, 11.4)
Concomitant diseases (%) 17 (100.0)
Oncologic disorders 7 (41.2)
Neuroblastoma 5 (29.4)
AML 2 (11.7)
Hematologic disorders (%) 10 (58.8)
Severe aplastic anemia 5 (29.4)
Hemolytic anemia 2 (11.7)
Congenital dyserythropoietic anemia 1 (5.9)
Pure red cell aplasia 1 (5.9)
Myelodysplastic syndrome
(refractory anemia)
1 (5.9)
Table 2. Changes in biochemical markers of the hematologic, 
hepatic, and renal systems at baseline and end of deferiprone 
treatment.
Parameters
Baseline 
(Mean±SE)
End of Study
(Mean±SE)
P
a)
WBC (/μL) 6,842.4±843.0 6,442.4±1,031.9 0.679
Hb (g/dL) 9.3±0.7 9.7±0.8 0.361
Hct (%) 27.7±2.2 28.5±2.2 0.438
PLT (×10
3/μL) 165.4±42.2 222.6±56.7 0.216
AST (IU/L) 63.4±15.9 46.3±9.6 0.097
ALT (IU/L) 113.5±47.4 79.4±26.5 0.184
Cr (mg/dL) 0.6±0.1 0.7±0.1 0.044
a)Student’s t-test for statistical analysis.
hematologic and/or oncologic patients with a high iron 
overload.
MATERIALS AND METHODS
  Seventeen patients (6 boys and 11 girls; age: 1.1-20.4 years; 
median: 10.6 years) from 7 hospitals who were treated with 
deferiprone from January 2006 to September 2009 were en-
rolled in this study. All patients received deferiprone as 
the first iron-chelating agent. The median dose of deferiprone 
was 25 mg/kg (range: 20-40 mg/kg). Seven patients were 
diagnosed with oncologic diseases and 10 with hematologic 
diseases. Among the oncologic patients, 5 were diagnosed 
with neuroblastoma and 2 were diagnosed with acute mye-
loid leukemia (AML). Hematologic disorders included severe 
aplastic anemia (SAA; 5 patients) hemolytic anemia (2 pa-
tients), congenital dyserythropoietic anemia (1 patient), pure 
red cell aplasia (1 patient), and myelodysplastic syndrome 
or refractory anemia (1 patient). The time period between 
diagnosis and the start of deferiprone treatment ranged from 
0.7 to 20.3 years (median: 3.6 years). The median treatment 
duration of this study was 11.4 months (range: 1.4-39.6 
months). All patients had received RBC transfusions (3-330 
units; median: 48 units) for a median of 3 years (range: 
1-13 years) (Table 1).
  Patient data were collected from 7 hospitals in Korea in 
a retrospective manner, and the participating institutions 
were approved for inclusion in this study by the institutional 
review board of each hospital. Data collected for each patient 
consisted of the following: complete blood count (CBC); 
ferritin, serum creatinine, aspartate aminotransferase (AST), 
and alanine aminotransferase (ALT) levels; concomitantly 
used drugs; and complications occurring between the start 
and end of deferiprone use. Toxicities were evaluated using 
common toxicity criteria (CTC; version 3.0). Cardiac evalua-
tion was limited to patients with a history of the symptoms 
of heart failure and/or arrhythmia. In the present study, 
however, no cardiac symptoms were reported. To evaluate 
the efficacy and safety of deferiprone treatment, biochemical 
parameters such as serum ferritin and liver enzymes were 
analyzed using the Student t-test. All parameters are presented 
as mean±standard error (SE). P-values less than 0.05 were 
considered statistically significant.
RESULTS
  Serum ferritin levels were 4,677.8±1,130.9 μg/L at baseline 
compared to 3,363.9±1,149.7 μg/L at the end of deferiprone 
treatment (P=0.033; Fig. 1). Other hematologic parameters 
such as hemoglobin, white blood cell (WBC) count, and 
platelet count showed no significant changes (Table 2). Korean J Hematol 2010;45:58-61.
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Biochemical parameters for liver toxicity (AST and ALT) 
showed some diminution at the end of treatment but did 
not reach the level of statistical significance. Serum creatinine 
levels showed a slight increase at the end of deferiprone 
use, but levels were below normal both during and after 
the deferiprone treatment period (Table 2).
  One patient experienced a mild degree of leucopenia (WBC 
count=1,870/μL; neutrophil count ＞1,000/μL), and medi-
cation was stopped immediately. The patient, a diabetic who 
had used insulin during the study period, received defer-
iprone 30 mg/kg for 9 months, followed by an increase in 
drug dose to 45 mg/kg. Seven months after the dose of defer-
iprone was increased, the patient’s CBC indicated leucopenia. 
After cessation of the drug, the patient’s WBC count gradu-
ally normalized.
DISCUSSION
  In this study, serum ferritin levels declined significantly 
from baseline to end of treatment course (4,677.8±1,130.9 
μg/L vs. 3,363.9±1,149.7 μg/L; P=0.033; Fig. 1). Only 1 patient 
stopped taking medication owing to complications. This is 
similar to the results of previous studies in which deferiprone 
treatment prevented the progression of iron overload in 
transfusion-dependent patients, as demonstrated by the se-
quential assessments of serum ferritin concentrations [17-19]. 
In addition, the efficacy of deferiprone has been shown to 
be equivalent to that of deferoxamine in some studies [12-16].
  While some adverse events were expected in the present 
study, complications occurred in only 1 patient (5.9%). No 
liver enzyme elevation or agranulocytosis (severe neu-
tropenia, defined as an absolute neutrophil count [ANC] 
＜500/μL) was reported; however, 1 case of neutropenia 
(defined as ANC ＞500/μL but ＜1,500/μL) was identified. 
Serum creatinine concentrations increased significantly; 
however, the levels of serum creatinine at the end of the 
study were in the clinically normal range (0.7±0.1 mg/dL). 
In a large, multicenter, long-term study of deferiprone treat-
ment, the incidence of agranulocytosis was 1% [20]. This 
corresponds to a rate of 0.4 episodes per 100 patient-years 
of therapy. In the present study, agranulocytosis did not 
develop because of the small number of patients and the 
short study period (22.9 patient-years; data not shown). 
However, the overall incidence of neutropenia corresponds 
to a rate of 2.5 per 100 patient-years of exposure [20]. This 
incidence explains the results of the present study. Although 
the mechanism of neutropenia development may differ from 
the mechanism that results in agranulocytosis, thalassemia 
patients not treated with deferiprone are known to exhibit 
transient drops in the neutrophil count to a level defined 
as neutropenia [21]. In some studies, deferoxamine-treated 
patients experienced at least 1 episode of neutropenia, and 
these episodes are likely to be related to overactivity of 
the spleen, a condition that is often present in thalassemia 
patients [20, 22, 23].
  The limitations of this study were the small number of 
patients, short period of follow-up time, and the hetero-
genous disease group. Seven patients had a malignant disease 
such as neuroblastoma and AML. Most studies on iron-chelat-
ing agents applied these agents to targeted hematologic dis-
orders such as thalassemia. However, results of the present 
study show the effectiveness of deferiprone in pediatric pa-
tients with malignant or benign hematologic disease for 
which transfusion is needed during the course of treatment.
  In conclusion, deferiprone treatment is relatively safe for 
pediatric patients suffering from various hematologic and 
oncologic diseases for which RBC transfusion is needed dur-
ing treatment. However, critical complications such as neu-
tropenia remain a concern.
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